Drug intelligence / Profile preview

buspirone + perphenazine

Development stage: Preclinical
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral

Overview

A combination of buspirone, an anxiolytic agent, and perphenazine, a phenothiazine antipsychotic. This combination has been studied as an alternative treatment for schizophrenia patients who experienced weight gain on other antipsychotic medications such as olanzapine or risperidone. In a pilot study, this combination showed no relapse of psychotic symptoms, no exacerbation of extrapyramidal side effects, and resulted in weight reduction.

Targets

DRD4 (Dopamine D4 Receptor)HTR2A (Serotonin receptor 5-HT2A)ADRA2A (α2A)DRD1 (Dopamine D1 Receptor)ADRA1A (α1A)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))

Beyond the preview

Go deeper on buspirone + perphenazine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on buspirone + perphenazine.

Explore the full profile